# US 2023/0065577 A1 · Combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065577 A1
- Document ID: US20230065577A1
- Status: Published application
- Kind: A1
- Application number: 17/757,490
- Filed: 2020-12-16
- Published: 2023-03-02
- Earliest claimed: 2019-12-20
- Assignees: Recurium IP Holdings, LLC
- Applicants: Recurium IP Holdings, LLC
- Inventors: Ahmed Abdi Samatar; Hooman Izadi; Peter Qinhua Huang; Joseph Robert Pinchman; Kevin Duane Bunker; Fernando Donate
- Web page: https://patentgrep.com/patent/US20230065577A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

## Claims

### Claim 1

Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (A) and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:
the Compound (A) has the structure:
wherein:
R1 is selected from the group consisting of hydrogen, halogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl, a substituted or unsubstituted C3-C6 cycloalkyl, a substituted or unsubstituted C1-C6 alkoxy, an unsubstituted mono-C1-C6 alkylamine and an unsubstituted di-C1-C6 alkylamine;
each R2 is independently selected from the group consisting of halogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl and a substituted or unsubstituted C3-C6 cycloalkyl; or
when m is 2 or 3, each R2 is independently selected from the group consisting of halogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl and a substituted or unsubstituted C3-C6 cycloalkyl, or two R2 groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted C3-C6 cycloalkyl or a substituted or unsubstituted 3 to 6 membered heterocyclyl;
R4 is selected from the group consisting of NO2, S(O)R6, SO2R6, halogen, cyano and an unsubstituted C1-C6 haloalkyl;
R5 is —X1-(Alk1)n-R7;
Alk1 is selected from an unsubstituted C1-C4 alkylene and a C1-C4 alkylene substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, an unsubstituted C1-C3 alkyl and an unsubstituted C1-C3 haloalkyl;
R6 is selected from the group consisting of a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl and a substituted or unsubstituted C3-C6 cycloalkyl;
R7 is selected from a substituted or unsubstituted C1-C6 alkoxy, a substituted or unsubstituted C3-C10 cycloalkyl, a substituted or unsubstituted 3 to 10 membered heterocyclyl, hydroxy, amino, a substituted or unsubstituted mono-substituted amine group, a substituted or unsubstituted di-substituted amine group, a substituted or unsubstituted N-carbamyl, a substituted or unsubstituted C-amido and a substituted or unsubstituted N-amido;
m is 0, 1, 2 or 3;
n is selected from the group consisting of 0 and 1; and
X1 is selected from the group consisting of —O—, —S— and —NH—; and
the one or more of Compound (B) is a WEE1 inhibitor, or a pharmaceutically acceptable salt thereof;
wherein the WEE1 inhibitor is selected from the group consisting of
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 2 (depends on 1)

The use of claim 1, wherein the Compound (A) is selected from the group consisting of:
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 3 (depends on 1, 2)

The use of claim 1 or 2, wherein the WEE1 inhibitor is
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2)

The use of claim 1 or 2, wherein the WEE1 inhibitor is NUV-569, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1, 2)

The use of claim 1 or 2, wherein the WEE1 inhibitor is IMP7068, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1, 2)

The use of claim 1 or 2, wherein the WEE1 inhibitor is Debio 0123, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1, 2)

The use of claim 1 or 2, wherein the WEE1 inhibitor is
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1, 2)

The use of claim 1 or 2, wherein the WEE1 inhibitor is
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The use of any one of claims 1-8, wherein the disease or condition is a hematological malignancy.

### Claim 10 (depends on 9)

The use of claim 9, wherein the hematological malignancy is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML).

### Claim 11 (depends on 9)

The use of claim 9, wherein the hematological malignancy is non-Hodgkin's lymphoma.

### Claim 12 (depends on 9)

The use of claim 9, wherein the hematological malignancy is Multiple Myeloma and blastic plasmacytoid dendritic cell neoplasm.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The use of any one of claims 1-8, wherein the disease or condition is a solid tumor.

### Claim 14 (depends on 13)

The use of claim 13, wherein the disease or condition is selected from the group consisting of a bladder cancer, a brain cancer, a breast cancer, a cervical cancer, a choriocarcinoma, a cervicocerebral cancer, a colon cancer, an endometrial cancer, an esophageal cancer, a gallbladder/bile duct cancer, a head and neck cancer (including oral cancer), a hepatocellular cancer, a lung cancer, a non-small cell cancer, a mesothelioma, an ovarian cancer, an osteosarcoma, a pancreatic cancer, a penis cancer, an anal cancer, a prostate cancer, a testicular cancer, a small cell cancer, a small cell lung cancer, a stomach cancer, a rectal cancer, a renal pelvis/ureter cancer, a skin cancer, a soft tissue sarcoma, a stomach cancer, a testicular cancer, a thyroid cancer, an uterus body cancer and an uterocervical cancer.

### Claim 15 (depends on 14)

The use of claim 14, wherein the disease or condition is a breast cancer.

### Claim 16 (depends on 14)

The use of claim 14, wherein the disease or condition is small cell lung cancer.

### Claim 17 (depends on 14)

The use of claim 14, wherein the disease or condition is pancreatic cancer.
